Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Kenvue Inc.

The board of directors of Dominion Energy has declared a quarterly dividend of 66.75 cents per share of common stock. Dividends are payable on Sept. 20, 2026, to shareholders of record at the close of business Sept. 4, 2026. This is the 394th consecutive dividend that Dominion Energy or its predecessor company has paid holders of common stock. The company's last quarterly dividend was declared May 5, 2026.
Merck, known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the fourth quarter of 2026. Payment will be made on October 7, 2026, to shareholders of record at the close of business on September 15, 2026.
Cintas announced that the Company's Board of Directors approved a quarterly cash dividend of $0.52 per share of common stock payable on September 15, 2026, to shareholders of record at the close of business on August 14, 2026. Cintas has a strong record of returning capital to its shareholders and has consistently raised its dividend each year since Cintas' initial public offering 43 years ago in 1983.
Linde announced its Board of Directors has declared a quarterly dividend of $1.60 per share. The dividend is payable on September 17, 2026, to shareholders of record on September 3, 2026.
Kenvue today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026.
VIDEO: Daily Dividend Report: D,MRK,CTAS,LIN,KVUE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Daily Dividend Report: D,MRK,CTAS,LIN,KVUE

(RTTNews) - Kenvue Inc. (KVUE) announced that the FDA has approved TYLENOL with Naproxen, the first and only over the counter fixed dose combination of acetaminophen (650 mg) and naproxen sodium (220 mg) for pain relief.
This new formulation combines the fast-acting relief of acetaminophen with the long-lasting anti-inflammatory effect of naproxen sodium, beginning to work in under 30 minutes and providing up to 12 hours of relief in a single dose. The approval addresses a critical gap in pain management, as surveys show that three out of four persistent pain sufferers are dissatisfied with current options.
The FDA decision is supported by eight clinical studies demonstrating superior pain relief compared to acetaminophen or naproxen sodium alone. TYLENOL with Naproxen has been granted three years of exclusivity, underscoring its significance in expanding non-opioid pain relief choices.
Company executives emphasized that the product simplifies pain management by eliminating the need to coordinate multiple medications.
Dr. Rajesh Mishra, Chief Medical Officer, Kenvue, noted that the combination offers "fast onset, 12-hour duration, and the safety profile of two well-established non-opioid ingredients in one fixed-dose."
TYLENOL with Naproxen will be available soon at major U.S. retailers nationwide. KVUE has traded between $14.02 and $22.87 over the past year. The stock closed Friday's trading at $19.28, up 2.01%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

FDA Clears Kenvue's TYLENOL With Naproxen, First OTC Fixed-Dose Combination

The NASDAQ 100 After Hours Indicator is down -13.85 to 28,590.38. The total After hours volume is currently 108,486,190 shares traded.
The following are the most active stocks for the after hours session:
NVIDIA Corporation (NVDA) is -0.78 at $202.50, with 4,403,392 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jul 2026. The consensus EPS forecast is $2.01. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
Comcast Corporation (CMCSA) is unchanged at $23.78, with 2,764,602 shares traded.CMCSA is scheduled to provide an earnings report on 7/23/2026, for the fiscal quarter ending Jun2026. The consensus earnings per share forecast is 0.97 per share, which represents a 125 percent increase over the EPS one Year Ago
Intel Corporation (INTC) is -0.2 at $96.86, with 2,406,461 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2026. The consensus EPS forecast is $0.15. INTC is scheduled to provide an earnings report on 7/23/2026, for the fiscal quarter ending Jun2026. The consensus earnings per share forecast is 0.1 per share, which represents a -26 percent increase over the EPS one Year Ago
HDFC Bank Limited (HDB) is -0.0155 at $23.58, with 2,342,792 shares traded. As reported by Zacks, the current mean recommendation for HDB is in the "buy range".
Kenvue Inc. (KVUE) is unchanged at $19.02, with 2,183,366 shares traded. KVUE's current last sale is 100.11% of the target price of $19.
Apple Inc. (AAPL) is +0.1 at $326.69, with 2,179,506 shares traded. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Walmart Inc. (WMT) is unchanged at $112.20, with 2,098,174 shares traded. As reported by Zacks, the current mean recommendation for WMT is in the "buy range".
Palantir Technologies Inc. (PLTR) is -0.5 at $134.35, with 2,074,459 shares traded. As reported by Zacks, the current mean recommendation for PLTR is in the "buy range".
Devon Energy Corporation (DVN) is unchanged at $43.78, with 2,035,913 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2026. The consensus EPS forecast is $1.27. As reported by Zacks, the current mean recommendation for DVN is in the "buy range".
Verizon Communications Inc. (VZ) is unchanged at $43.50, with 1,703,671 shares traded.VZ is scheduled to provide an earnings report on 7/24/2026, for the fiscal quarter ending Jun2026. The consensus earnings per share forecast is 1.27 per share, which represents a 122 percent increase over the EPS one Year Ago
Element Solutions Inc. (ESI) is unchanged at $36.46, with 1,640,212 shares traded.ESI is scheduled to provide an earnings report on 7/27/2026, for the fiscal quarter ending Jun2026. The consensus earnings per share forecast is 0.43 per share, which represents a 37 percent increase over the EPS one Year Ago
United Parcel Service, Inc. (UPS) is unchanged at $113.15, with 1,580,755 shares traded. UPS's current last sale is 94.69% of the target price of $119.5.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

After Hours Most Active for Jul 20, 2026 : NVDA, CMCSA, INTC, HDB, KVUE, AAPL, WMT, PLTR, DVN, VZ, ESI, UPS

Key Points
Kimberly-Clark has raised its dividend for 54 consecutive years.
It recently acquired Kenvue, which makes personal-care products.
The paper products maker also offers a high-yielding dividend.
A Dividend King is a company that has increased its dividend for at least 50 years in a row. There are currently only 57 that can wear this crown.
One of them is Kimberly-Clark (NASDAQ: KMB), the venerable company that makes tissues, paper towels, diapers, and other paper-based family-care products. It has increased its dividend for 54 straight years, making its stock a Dividend King. But it also pays out one of the highest yields among Dividend Kings -- 4.7% right now. The combination makes it one of the best, most reliable dividend stocks you can buy.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
But the stock is not just a buy for its royal dividend -- it's also positioned to deliver some solid returns. Here's why.
A strategic shift toward higher-margin products
Kimberly-Clark stock is up about 11% year to date (with dividends reinvested), but its total returns are down about 10% over the past 12 months. Its long-term returns aren't great either, as it averaged a drop of 1% over the past five years and a total rise of only 1% over the past decade.
Its main utility for investors has been to provide excellent dividend income, and some downside protection when markets go south. But some recent developments could position the company to generate some decent returns.
Earlier this month, Kimberly-Clark struck a deal with pulp supplier Suzano (NYSE: SUZ) to form a new paper products company, Arbex. This benefits Kimberly-Clark by offloading its lower-margin paper-towel and tissue business, allowing it to focus on its higher-margin personal-care products. Kimberly-Clark also has a licensing agreement with Arbex to license its paper brands, so that will generate some licensing royalties.
A greater focus on absorbing its Kenvue acquisition
More importantly, it frees up resources for Kimberly-Clark to integrate its pending acquisition of Kenvue (NYSE: KVUE).
Kenvue, which makes skincare products like Aveeno and consumer health products like Band-Aid, Tylenol, and Listerine (to name just a few), spun off from Johnson & Johnson in 2023. Kimberly-Clark sees it as a complementary fit, creating a global health and wellness leader, and expects the combination to maximize each company's strengths and accelerate growth.
Kimberly-Clark anticipates approximately $1.9 billion in cost synergies and roughly $500 million in profit from revenue synergies, within three to four years of the deal closing. It also expects to spend about $2.5 billion to realize these benefits in the first two years.
Long live the Dividend King
Analysts are generally bullish on the acquisition, with several raising their price targets for the stock in recent weeks. They have a median price target of $113 per share, suggesting 5% upside. Shares are also cheap, trading at 14 times earnings.
I think Kimberly-Clark is a buy for its dividend alone. But investors may also see the added benefit of solid long-term returns following the major shift from this 154-year-old company.
Should you buy stock in Kimberly-Clark right now?
Before you buy stock in Kimberly-Clark, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kimberly-Clark wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $371,842!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,244,783!*
Now, it’s worth noting Stock Advisor’s total average return is 900% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Dave Kovaleski has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Kenvue. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

An Overlooked Dividend King With a 54-Year Winning Streak Worth Buying Now

Key Points
The healthcare giant is on track to report full-year revenue of more than $100 billion.
The company raised guidance for annual revenue and earnings per share.
Johnson & Johnson (NYSE: JNJ) has been a top-performing stock this year. Investors, in many cases rotating out of riskier assets, have looked for companies with a strong track record of earnings growth, solid competitive positions, and a revenue stream they can count on -- and J&J fits the bill.
As a healthcare player, J&J sells pharmaceuticals and medical devices that ensure a certain level of revenue, as patients need their procedures no matter what direction the stock market takes. Over time, the company's in-house research and acquisitions have built a market-leading portfolio that has kept earnings climbing. Investors, concerned about geopolitical uncertainties and risks to the artificial intelligence (AI) growth story, turned to J&J in the first half, sending the stock to a 22% gain.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Last week, J&J delivered a blowout earnings report and increased full-year forecasts. But is it too late to buy this healthcare giant? Let's find out.
A household name
You might know J&J best for consumer products that you regularly use, from Band-Aid brand bandages to Tylenol. They've made J&J a household name. But the company actually spun off its consumer health business, which includes these products, as Kenvue a few years ago. This was in an effort to boost growth, with the idea of dedicating all of its resources to the higher-growth areas of pharmaceuticals and medtech.
The Kenvue spinoff came at a key moment, as J&J prepared to lose exclusivity of its blockbuster immunology drug Stelara. At its peak in 2024, Stelara brought in more than $10 billion. But the impending entry of rivals meant that Stelara sales would drop drastically.
J&J's move was a wise one, and the latest quarter illustrates this. Solid performance from immunology drug Tremfya and leading multiple myeloma drug Darzalex compensated for Stelara declines and drove more than 6% growth to $25 billion in total revenue -- keeping J&J on track to reach its goal of $100 billion in annual revenue. Darzalex revenue jumped 18% to more than $4.2 billion in the quarter, while Tremfya soared 72% to $2 billion.
A recent headwind
J&J faced one headwind in particular in the quarter. The medtech division saw some weakness -- in an interview with CNBC, chief financial officer Joseph Wolk said sales of Abiomed heart pumps slipped after the release of a study questioning the use of Impella pumps during some high-risk procedures. Wolk said J&J plans to release data in the first half of next year that should alleviate concerns. It's important to remember that the company has 28 products or platforms that bring in revenue of at least $1 billion, offering it the fuel needed for ongoing growth.
J&J increased its full-year sales guidance to $101.1 billion at the midpoint from the previous estimate of $100.8. And it boosted adjusted earnings per share guidance to $11.68 at the midpoint from $11.55.
Should you buy J&J?
Now, let's return to our question: Is it too late to buy shares of this healthcare giant after its strong run so far this year?
Today, J&J isn't dirt cheap. In fact, it's trading close to its highest in relation to forward earnings estimates.
It's possible that, given this valuation level, the stock may dip in the weeks or months to come, offering investors a better buying opportunity. Value investors, for example, probably should wait before jumping to get in on J&J stock at this level.
That said, it's important to note that J&J offers investors many strengths, from its broad portfolio of blockbuster products to leadership in key treatment areas such as multiple myeloma and immunology, through the two top drugs mentioned above. J&J is also a Dividend King, having increased its dividend payments for more than 50 consecutive years. So, investors focused on dividend growth may find it worthwhile to buy shares of J&J even at today's valuation -- it's high, but not outrageous.
All of this means your investment style and priorities should guide your decision. The best news of all is that this top pharma stock likely has room to run over the long term.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $371,842!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,244,783!*
Now, it’s worth noting Stock Advisor’s total average return is 900% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Kenvue. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?

Key Points
Ken Griffin has a long track record of stock market gains, and he extended this into the first quarter of 2026.
This Griffin stock makes a great addition to any portfolio, but two elements make it particularly attractive for cautious investors.
Investors pay careful attention to Ken Griffin's moves for one major reason: The founder of Citadel has an extremely solid track record of success. Citadel, which oversees $69 billion, in January was named the most profitable hedge fund ever, winning this accolade for the fourth straight year.
Griffin's funds also carried their success through the first half of this year, with positive returns across strategies, according to a recent CNBC report. The billionaire uses a variety of techniques, including focuses on in-depth research and managing risk, in order to deliver the strongest possible returns in any market environment.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
With all of this in mind, let's consider one of the billionaire's latest moves. He boosted his stake in one particular Dividend King by 146% in the first quarter. Here's why it's an ideal choice for investors who are uncomfortable with risk.
A name you may know well
This particular stock is a name you might know well, thanks to various consumer health products the company used to sell -- from Band-Aid bandages to Tylenol. It spun off that business as Kenvue a few years ago in order to focus on its two core businesses of pharmaceuticals and medtech. I'm talking about Johnson & Johnson (NYSE: JNJ).
In the first quarter, Ken Griffin increased his position in J&J by 146% and now holds 1,930,976 shares. The stock, at 0.08% of the portfolio, isn't a huge position -- but its presence there since 2017 suggests Griffin recognizes J&J as a key long-term winner.
Now, let's talk about why this stock is such a great holding for risk-averse investors. First, it's important to consider the Kenvue spinoff. Though J&J may have become a household name thanks to its consumer products, consumer health actually wasn't a huge growth driver for the company. Pharmaceuticals -- known as the innovative medicine business -- and medtech offered greater growth potential, so J&J wanted to devote more resources to these units.
The bet has already proven to be a smart one, as revenue has climbed in recent quarters. The latest one is the perfect example. Innovative medicine sales jumped 11%, while medtech sales advanced more than 7%. And overall worldwide sales increased nearly 10% to more than $24 billion.
28 billion-dollar platforms
One element that makes J&J a low-risk stock is the fact that this growth isn't driven by a product or two. The pharma giant has 28 platforms or products that bring in at least $1 billion annually. And J&J is on track to increase this number. The more blockbusters a company has, the less vulnerable it is when a particular product loses exclusivity.
J&J has proven its ability to overcome such challenges. The company's immunology blockbuster Stelara saw the impact of this last year, yet J&J's other top drugs compensated, and the company even said its performance placed the loss of exclusivity "in the rearview mirror." In spite of a 41% drop in Stelara sales, total sales advanced 6% last year.
So, investors can count on a solid portfolio of products delivering growth at J&J. It's also important to note that medical treatments are essentials, so even during difficult economic times, sales of these types of products generally hold up well.
Now here's the second major element that makes J&J the ideal stock for cautious investors. The company is a Dividend King, meaning it's increased these payments to shareholders for more than 50 consecutive years. This shows a true commitment to dividend growth. That, along with J&J's huge level of free cash flow, supports the idea of an increasing dividend over the years to come.
J&J pays a dividend of $5.36 per share, representing a dividend yield of 2% and surpassing the 1.1% yield of the S&P 500. This focus on dividends is fantastic because it offers investors a recurrent source of income -- regardless of the performance of the market or even J&J stock.
This combination of dividend and business strength makes this Ken Griffin stock a great pick for a broad range of investors -- and a dream stock for those who are risk-averse.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $395,679!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,805!*
Now, it’s worth noting Stock Advisor’s total average return is 929% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Kenvue. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Billionaire Ken Griffin Boosted His Stake in This Dividend King by 146%. Here's Why It's a Dream Stock for Risk-Averse Investors.

Key Points
Among the 15 largest U.S. IPOs in history, the average stock declined 30% from its IPO price at some point during the first year.
The number of SpaceX shares available for public trading will increase greatly in the next few months, putting downward pressure on the price.
SpaceX currently trades at 101 times sales, which makes it the most expensive stock in the Nasdaq-100 by a wide margin.
Space Exploration Technologies (NASDAQ: SPCX) made its public debut on June 12. The initial public offering (IPO) was historic not only because the company raised a record $75 billion, but also because its market value was an unprecedented $1.7 trillion at the IPO price of $135 per share.
SpaceX soared 50% during the first three trading days, hitting a high of $202 per share amid strong demand from retail and institutional investors. But the stock has since fallen 26% to $150 per share because of anxiety about the company's recent bond offering and the upcoming lockup expiration dates.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Here's what investors need to know.
History says SpaceX stock could fall much further in the coming months
Since 1980, the average IPO stock has gained about 19% on the first trading day, according to Jay Ritter, professor emeritus of finance and director of the IPO initiative at the University of Florida. SpaceX fit that pattern perfectly. Shares closed at $161 on June 12, representing 19% upside from the IPO price of $135.
However, excitement surrounding IPOs tends to fade quickly, and companies that go public at large market values have historically performed poorly during the first year. The following chart lists the 15 largest U.S. IPO stocks (by market value at the IPO price) excluding SpaceX; for each stock, it shows (1) the one-year return and (2) the maximum drawdown in the first year relative to the IPO price.
IPO Stock
1-Year Return
Max Drawdown
Meta Platforms
(31%)
(53%)
Uber Technologies
(27%)
(67%)
Rivian Automotive
(58%)
4%
Coinbase Global
(41%)
(41%)
Venture Global
(59%)
(76%)
Coupang
(46%)
(48%)
General Motors
(34%)
(40%)
Airbnb
165%
84%
Visa
28%
(4%)
Kenvue
(13%)
(17%)
DoorDash
62%
11%
Rocket Companies
(3%)
(8%)
UiPath
(68%)
(68%)
Snowflake
170%
(57%)
Robinhood Markets
(76%)
(82%)
Average
(2%)
(23%)
Among the 15 largest U.S. IPOs, the average stock traded 2% below its IPO price after a year, but it dropped 23% from its IPO price at some point during the first year. Past results are never a guarantee of future returns, but we can use those numbers to make an educated guess about what SpaceX stock might do in the future.
If SpaceX's performance matches the historical average, the stock will trade near $132 per share (2% below its IPO price) by June 2027. That implies 11% downside from the current share price of $149. In that scenario, $20,000 invested in SpaceX today would be worth about $17,800 by June 2027.
But history also says SpaceX will drop 23% from its IPO price at some point in the first year. That would bring the stock to $104 per share, which implies 30% downside from the current price. In that scenario, $20,000 invested in SpaceX today would be worth about $14,000 at some point in the next year.
SpaceX shares available for public trading will increase sharply once lockups start expiring
SpaceX issued 555 million shares for its initial public offering, bringing the total number of shares outstanding to 13.1 billion. That means less than 5% of SpaceX stock is currently available for public trading, while the other 95% (held by employees and insiders) is subject to various lock-up periods.
Those lock-up periods start expiring in a few weeks. In late July or early August, following the company's second-quarter financial report, at least 20% of early release shares (about 911 million shares) will become eligible for public trading. That means the float will more than double to reach 1.5 billion shares.
However, lockup expirations don't stop there. Another 7% of early release shares (about 320 million shares) will become eligible for public trading at 70 days, 90 days, 105 days, 120 days, and 135 days post-IPO. That means the float will double again, reaching at least 3 billion shares by late October.
Here's the big picture: Stock prices are determined by supply and demand. The number of SpaceX shares available for public trading will increase greatly in the coming months, and the stock price could drop, perhaps sharply, as the market digests that supply increase.
So investors need not rush to buy SpaceX stock today. More attractive opportunities are likely to arise in the future. That is particularly true because the stock currently trades at 101 times sales, making it the most expensive stock in the Nasdaq-100 by a wide margin. Rocket Lab ranks second at 73 times sales.
Should you buy stock in Space Exploration Technologies right now?
Before you buy stock in Space Exploration Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Space Exploration Technologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $410,833!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,208,693!*
Now, it’s worth noting Stock Advisor’s total average return is 917% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of July 9, 2026.
Trevor Jennewine has positions in Visa. The Motley Fool has positions in and recommends Airbnb, DoorDash, Meta Platforms, Rocket Companies, Rocket Lab, Snowflake, Uber Technologies, UiPath, and Visa. The Motley Fool recommends Coinbase Global, Coupang, General Motors, and Kenvue. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

SpaceX Stock Is Down 26% From Its Post-IPO High. History Says a $20,000 Investment Will Be Worth This Much by Mid-2027.

Key Points
Kimberly-Clark’s portfolio of leading brands is about to get a whole lot bigger after its Kenvue acquisition.
The deal is expected to close before the end of the year.
The stock’s valuation is well below its historical average.
As of market close on July 7, the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) are up 9.6% and 11.1% year to date (YTD), respectively, and hovering around all-time highs. The tech sector -- which makes up 38% of the index -- is largely responsible for the strong gains because it is up 24.5% YTD.
However, some noteworthy value stocks are doing even better than the tech-heavy S&P 500. Kimberly-Clark (NASDAQ: KMB) is up 13.7% YTD, and that's without even factoring in two $1.28 per share dividend payments. Earlier this year, Kimberly-Clark raised its dividend for the 54th consecutive year, retaining its spot on the list of Dividend Kings, which have at least 50 consecutive years of dividend increases.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Here's why Kimberly-Clark remains a great dividend stock to buy for the second half of the year.
1. Kimberly-Clark is recession-resistant
Kimberly-Clark has a portfolio of leading household and personal care brands, many of which are paper-based. Its crown jewel is Huggies, which is the No. 2 diaper brand in the world behind Pampers. Other notable brands include Kleenex, Kotex, Scott, and Cottonelle.
Demand for these products tends to be consistent across economic cycles, though Kimberly-Clark's margins have been under pressure due to rising costs and inflationary pressures on consumer spending. In Kimberly-Clark's first-quarter 2026 earnings call, it forecasted $150 million to $170 million in additional costs if oil remained around $100 per barrel. Oil prices have come down significantly since that late Aprilearnings call but the months when oil was elevated will affect its full-year margins.
However, Kimberly-Clark is implementing productivity initiatives, new pricing with suppliers, and hedging programs to improve margins. Kimberly-Clark's chief financial officer, Nelson Urdaneta, said the following on the Q1 2026earnings call
I'd also remind everyone that we've got a solid track record over the last four years of recovering any input cost inflation and actually expanding margins. If you look at 2023 through 2025, we expanded both gross margins and operating profit margins beyond the levels pre-pandemic. So we're confident in our ability to cover all these input costs over time.
Kimberly-Clark isn't immune to consumer spending trends or macroeconomic factors, but it has done a good job adjusting to the new normal of cost inflation.
2. A major acquisition is right around the corner
In November 2025, Kimberly-Clark announced the acquisition of Kenvue (NYSE: KVUE). The consumer health company spun off from Johnson & Johnson in August 2023 and owns many noteworthy brands, including Aveeno, Neutrogena, Tylenol, Listerine, Johnson's, and BAND-AID.
Since then, Kimberly-Clark and Kenvue shareholders have overwhelmingly approved the acquisition, and Kimberly-Clark has moved forward with key organizational and leadership decisions.
The deal will diversify Kimberly-Clark's revenue streams and enhance its resilience in a recession. Kimberly-Clark expects the transaction to close before the end of the year.
3. Kimberly-Clark is dirt cheap
You may think that Kimberly-Clark would command a premium valuation, given that its stock price is outpacing the S&P 500 and Nasdaq in 2026. However, Kimberly-Clark fell 23% last year and is down 18.1% over the last decade.
Kimberly-Clark now trades at just 15.2 times analyst consensus 2026 earnings estimates of $7.54 per share. Its 10-year median price-to-earnings ratio is 21.9.
A top high-yield dividend stock to buy now
Investors who believe the Kenvue acquisition is the right move are getting a chance to buy Kimberly-Clark at a dirt cheap valuation. Kimberly-Clark expects the combined company to deliver $2.1 billion in annual run rate synergies by the second year following the acquisition, unlocking operating leverage and boosting margins.
In the meantime, investors can count on Kimberly-Clark's high-yield dividend. Although a high yield can sometimes indicate that a dividend is becoming unsustainable, Kimberly-Clark's earnings and free cash flow still exceed its payout.
With an established and recession-resistant portfolio of brands, Kimberly-Clark stands out as an attractive value stock for investors looking for an alternative to high-flying growth stocks. Unlike hyperscaler cloud computing companies, Kimberly-Clark isn't spending a ton of capital expenditures on big ideas that it needs to pay off. Rather, it is a stable stalwart that has rewarded income investors for decades.
Therefore, Kimberly-Clark can continue to outperform the S&P 500 and Nasdaq because its earnings growth expectations are already low. So even decent results would likely be received well by investors. However, Kimberly-Clark isn't without its risks.
If the Kenvue acquisition doesn't go as smoothly as planned or fails to unlock the cost savings Kimberly-Clark hopes for, it could make its dividend less affordable, which could strain its balance sheet. The combined company must also prove it can extract value from a larger portfolio of brands, which comes with a slew of execution challenges from a new leadership team.
Therefore, some investors may want to wait for the dust to settle after the Kenvue acquisition before buying the stock. Investors who don't mind the uncertainty can scoop up shares at an attractive valuation.
Should you buy stock in Kimberly-Clark right now?
Before you buy stock in Kimberly-Clark, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kimberly-Clark wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,200,223!*
Now, it’s worth noting Stock Advisor’s total average return is 916% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Daniel Foelber has positions in Kenvue and Kimberly-Clark. The Motley Fool recommends Johnson & Johnson and Kenvue. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This 4.5%-Yielding Dividend Stock Is Beating the S&P 500 and the Nasdaq. 3 Reasons That Can Continue in the Second Half of 2026

Key Points
Colgate-Palmolive doesn’t depend on the U.S. market to drive sales growth.
The company’s margins are strong, although they have ticked down in recent years.
Colgate-Palmolive is expensive for all the right reasons.
As of market close on July 3, the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq-100 are up 9.3% and 16.2%, respectively, year to date (YTD). This is well ahead of their historical average annual gains. The tech sector, especially semiconductor stocks, has been the driver of broader market returns. But that doesn't mean all value stocks are underperforming the major indexes.
Colgate-Palmolive (NYSE: CL) is up 20.4% YTD. And it's also an ultra-reliable dividend stock that has paid uninterrupted dividends since 1895 and has increased its payout for 63 consecutive years. That streak earns Colgate-Palmolive a spot on the list of Dividend Kings, which are companies that have paid and increased their dividends for at least 50 consecutive years.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Here's why Colgate-Palmolive remains a top buy now even after its recent run-up.
Colgate-Palmolive is at the top of its game
Colgate-Palmolive has been a standout in the household and personal products industry. The company is guiding for 2026 net sales growth of 2% to 6% and organic sales growth of 1% to 4% at a time when many of its peers are experiencing sales declines. And even with margins under pressure, Colgate-Palmolive remains one of the most profitable companies in its industry. By comparison, Unilever, Kenvue, Church & Dwight, Clorox, Kimberly-Clark, and Estee Lauder all have operating margins under 20%.
The industry has been dealing with inflationary pressures and consumer resistance to price increases. But Colgate-Palmolive has done a masterful job of navigating these challenges through its elite brand portfolio, highly efficient supply chain and operations, and geographic diversification.
In addition to its flagship Colgate and Palmolive brands, the company owns Softsoap, Irish Spring, Tom's of Maine, and Speed Stick, among others. One of Colgate-Palmolive's top brands, Hill's Pet Nutrition, made up 23% of total 2025 sales.
Without factoring in Hill's, Europe, Middle East, and Africa (EMEA), Latin America, and Asia Pacific sales are more than triple those of North America, which has helped make Colgate-Palmolive resistant to U.S.-specific inflationary pressures. In the first quarter of 2026, North America was the only region that reported declining net and organic sales, while Latin America and EMEA posted double-digit growth and total company net sales rose 8.4% year over year.
A dividend you can count on
Colgate-Palmolive is far from cheap -- trading at 25 times forward earnings -- because the stock price has been rising faster than the company's earnings growth. But Colgate-Palmolive deserves its premium valuation because its results are solid despite a difficult operating environment. This resilience is particularly appealing to risk-averse folks seeking a stable passive income stream to help supplement retirement income. If inflationary pressures ease and consumer spending improves, a rising tide will lift the broader household and personal products industry. But Colgate-Palmolive isn't dependent on those factors to drive sales growth.
Colgate-Palmolive yields 2.2%, which is good but not quite high-yield territory. Many of its peers offer higher yields because they distribute the vast majority of their cash flow to shareholders through dividends, whereas Colgate-Palmolive's dividend is highly affordable. Its trailing-12-month free cash flow per share is at an all-time high of $4.66, well over double its $2.06 per-share annualized dividend.
So while Colgate-Palmolive could easily afford to pay a higher dividend, the company prefers a balanced approach of using cash to reinvest in the business, paying a steadily growing (and manageable) dividend, and buying back stock. Colgate-Palmolive has reduced its share count by 10% over the last decade, which has helped make the stock a better value.
Investing in a market leader
Colgate-Palmolive's geographic diversification and portfolio of leading brands across pet nutrition and oral, personal, and home care make it highly recession resistant. The company continues to deliver solid growth through volume and price increases, while many of its peers face a difficult trade-off: either cutting prices to drive volume or keeping prices high at the expense of lower sales volumes.
All told, Colgate-Palmolive stands out as one of the most reliable dividend-paying stocks on the market. It's a top buy for the second half of the year for investors who don't mind paying a premium price for a quality company.
Should you buy stock in Colgate-Palmolive right now?
Before you buy stock in Colgate-Palmolive, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Colgate-Palmolive wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $418,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,195,804!*
Now, it’s worth noting Stock Advisor’s total average return is 918% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of July 7, 2026.
Daniel Foelber has positions in Estée Lauder Companies, Kenvue, and Kimberly Clark. The Motley Fool has positions in and recommends Colgate-Palmolive. The Motley Fool recommends Kenvue and Unilever. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Meet the Dividend King Stock That's Up 20% in 2026. Here's Why It Can Continue Outperforming the S&P 500 and Nasdaq-100 in the Second Half.

Beauty and cosmetics companies develop and market products for skincare, makeup, haircare and personal grooming to help people enhance their appearance. Investment in these companies presents a compelling case due to the sector's attractive growth potential.
The industry is buoyed by consistent customer demand, driven by a growing emphasis on personal care, self-expression, and an increasing middle class, particularly in emerging markets. These companies have demonstrated a robust performance, leveraging trends like clean beauty, gender-neutral products and technological innovations in skincare, as well as strong brand loyalty and a diverse product base.
Here,
we recommend five Beauty & Cosmetics stocks with a favorable Zacks Rank to buy for second-half 2026. These are: The Estée Lauder Companies Inc. EL, Helen of Troy Ltd. HELE, Nu Skin Enterprises Inc. NUS, Kenvue Inc. KVUE and Interparfums Inc. IPAR. Each of our picks currently carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The chart below shows the price performance of our five picks in the past month.
Image Source: Zacks Investment Research
The Estée Lauder Companies Inc.
Zacks Rank #1 Estée Lauder continues to gain traction as its Profit Recovery and Growth Plan supports margin recovery, operational efficiencies and stronger sales visibility. The Beauty Reimagined strategy, digital expansion and portfolio investments are helping EL improve innovation, consumer reach and online engagement, while emerging markets and improving trends in Mainland China provide long-term growth support.
Online sales growth, stronger social commerce momentum and broader distribution across Sephora, Amazon Premium Beauty and TikTok Shop continue to strengthen the company’s omnichannel position, positioning EL for a more sustainable long-term recovery and growth trajectory.
The Estée Lauder has an expected revenue and earnings growth rate of 3.7% and 31.9%, respectively, for the current year (ending June 2027). The Zacks Consensus Estimate for the current year’s earnings has improved 4.3% over the last 60 days.
Helen of Troy Ltd.
Zacks Rank #2 Helen of Troy is advancing its growth strategy through a focused portfolio of Leadership Brands, including OXO, Hydro Flask and Osprey, which continue to deliver solid performance supported by innovation, new product launches and strong e-commerce execution across channels and key retail partners.
HELE’s Elevate for Growth agenda, along with Project Pegasus, is driving efficiency, cost optimization and supply-chain improvements, helping mitigate tariff pressures and enhance long-term profitability.
HELE’s strategic initiatives such as global expansion, digital commerce investments, social selling and active portfolio management are expected to support growth, while strong cash flow generation is aiding debt reduction and improving overall financial flexibility.
Helen of Troy has an expected revenue and earnings growth rate of -0.1% and -3.1%, respectively, for the current year (ending February 2027). The Zacks Consensus Estimate for the current year’s earnings has remained the same over the last 30 days.
Nu Skin Enterprises Inc.
Zacks Rank #2 Nu Skin develops and distributes a wide range of premium cosmetics, beauty, personal care and wellness products. While NUS specializes in beauty and personal care, it also provides a wide range of nutritional products.
NUS’ products are available in markets worldwide. From a product perspective, NUS operates through two brand categories namely, Nu Skin and Pharmanex. The company offers premium quality personal care products under the Nu Skin brand banner, while nutritional supplements are marketed under Pharmanex.
NUS has evolved strongly in the skin care treatments arena, more particularly in anti-aging products. Some of the renowned brands of the company in skin care includes ageLOC and Epoch. NUS also provides a wide range of hair care and other personal care items.
The Nu Skin has an expected revenue and earnings growth rate of -4% and -21.3%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has remained same over the last 30 days.
Kenvue Inc.
Zacks Rank #2 Kenvue operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. KVUE operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. KVUE’s brand portfolio includes AVEENO, BAND-AID Brand Adhesive Bandages, JOHNSON'S, LISTERINE, NEUTROGENA, TYLENOL and ZYRTEC.
Kenvue has an expected revenue and earnings growth rate of 3.2% and 7.4%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 5.5% over the last 60 days.
Interparfums Inc.
Zacks Rank #2 Interparfums benefits from a diversified portfolio of leading fragrance brands, continued investments in premium and luxury offerings, expanding digital and travel retail channels, and a strong balance sheet that supports shareholder returns and future launches.
IPAR continues to invest in expanding and upgrading its brand portfolio. Alongside the ongoing rollout of its owned ultra-luxury brand Solferino, IPAR resumed distribution of Annick Goutal in early 2026 and reopened two Paris stores with another planned, building presence in higher-end fragrance.
Interparfums has an expected revenue and earnings growth rate of -0.1% and -8%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has remained the same over the last 60 days.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	22.75 19.07
Price/Sales	2.41 0.77
P/B	3.46 1.77
P/FCF	18.43 16.58

Indicator	TTM Median
ROE	20.19 14.73
ROA	7.97 6.75
ROI	9.14 9.35
Net Worth	36.73 1.25
Quick Ratio	0.70 0.79
Current Ratio	0.98 1.32

Indicator	TTM Median
Net Profit Margin	10.61 6.48
Operating Margin	17.15 8.48
Gross Margin	58.37 33.20
Return on tangible equity	0.00 23.46

Indicator	TTM Median
EPS	0.29 0.61
EPS Forecast	0.22 0.46
Revenue	3.91B 136.00M
Gross Profit	2.30B —
EBITDA	910.00M —

Kenvue Inc.

Recent quarterly and TTM performance

Valuation

Debts

Efficiency

Other ratios

Revenue